Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Oct
04
Today In Oncology
FDA Approves First-Line Pirtobrutinib for CLL-SLL
Lung Cancer AI Model May Predict Pneumonitis Risk From Immunotherapy
FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
Annual Report to the Nation: Progress Against Lung Cancer Drives Down Cancer Mortality
Are Narrower Negative Margins Linked to Higher Risk of DCIS Recurrence
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo